New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
06:44 EDTAERIAerie Pharmaceuticals initiates Phase 3 trials of Rhopressa
Aerie Pharmaceuticals announced that on July 11, dosing commenced of the first patients enrolled in the Phase 3 registration clinical trials of Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure in patients with glaucoma or ocular hypertension. Aerie anticipates total enrollment of approximately 1,300 patients in three Phase 3 registration trials of Rhopressa. The trials will measure efficacy over three months and safety over 12 months. The primary efficacy endpoint of the trials will be to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol. There will be two trials conducted in the United States, named “Rocket 1” and “Rocket 2,” and one safety-only study in Canada, named “Rocket 3.” Pending success of the studies and regulatory approval, Aerie expects RhopressaTM to compete against PGA products as an initial therapy for patients with IOPs of 26 mmHg or below at the time of diagnosis, which represents the significant majority of patients with glaucoma and ocular hypertension. Additionally, the company believes Rhopressa may be used as the add-on product of choice for patients on PGA therapy requiring further IOP lowering, due to its strong and consistent IOP-lowering effect, once-daily dosing and ability to target the trabecular meshwork.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2015
06:20 EDTAERIAerie Pharmaceuticals pullback a buying opportunity, says Brean Capital
Brean Capital analyst Difei Yang views the recent pullback in shares of Aerie Pharmaceuticals as a buying opportunity. After speaking to clients and company management, Yang sees no potential issues to warrant the recent selloff. The analyst points out that the company has more than $150M in cash, enough to support operations until 2017, making a capital raise very unlikely. Yang has a Buy rating on Aerie with a $48 price target.
September 25, 2015
17:14 EDTAERIIsrael Englander reports 9.1% passive stake in Aerie Pharmaceuticals
Subscribe for More Information
16:30 EDTAERIAdage Capital reports 5.84% passive stake in Aerie Pharmaceuticals
Subscribe for More Information
September 24, 2015
06:32 EDTAERIAerie Pharmaceuticals begins fourth Phase 3 clinical trial of Rhopressa
Subscribe for More Information
September 22, 2015
06:19 EDTAERIClinton to roll out plan to rein in prescription drug costs, USA Today reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use